Year Published:

2021 2020 2019 2018

Dec 1, 2020

Nov 16, 2020

Nov 16, 2020

Nov 11, 2020

Nov 10, 2020

Nov 5, 2020

Nov 2, 2020

Nov 1, 2020

Oct 29, 2020

Oct 22, 2020

Oct 13, 2022

Oct 9, 2020

Oct 1, 2020

Sep 28, 2020

Sep 16, 2020

Sep 2, 2020

Sep 1, 2020

Aug 6, 2020

Aug 6, 2020

Aug 5, 2020

Aug 3, 2020

Jul 24, 2020

Jul 1, 2020

Jun 18, 2020

Jun 1, 2020

May 26, 2020

May 12, 2020

May 7, 2020

May 7, 2020

May 1, 2020

Apr 30, 2020

Apr 6, 2020

Apr 1, 2020

Mar 31, 2020

Mar 26, 2020

Mar 18, 2020

Mar 2, 2020

Feb 27, 2020

Feb 20, 2020

Feb 18, 2020

Feb 10, 2020

Feb 3, 2020

Jan 2, 2020

Jan 2, 2020

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020

Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement

Dicerna to Participate in Upcoming Investor Conferences

Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020

Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020

Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020

Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)

Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference

Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary

Dicerna to Participate in Upcoming September Investor Conferences

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues

Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update

Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna to Report Second Quarter 2020 Financial Results and Host Virtual Research and Development Event on Aug. 6, 2020

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna to Participate in Jefferies Virtual Global Healthcare Conference

Dicerna to Present at Upcoming May Investor Conferences

Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update

Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020

Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan

Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic

Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020

Dicerna™ to Present at Upcoming Investor Conferences

Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors

Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases